[HTML][HTML] Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer
JL Chou, HY Su, LY Chen, YP Liao… - Laboratory …, 2010 - Elsevier
Resistance to TGF-β is frequently observed in ovarian cancer, and disrupted TGF-β/SMAD4
signaling results in the aberrant expression of downstream target genes in the disease. Our
previous study showed that ADAM19, a SMAD4 target gene, is downregulated through
epigenetic mechanisms in ovarian cancer with aberrant TGF-β/SMAD4 signaling. In this
study, we investigated the mechanism of downregulation of FBXO32, another SMAD4 target
gene, and the clinical significance of the loss of FBXO32 expression in ovarian cancer …
signaling results in the aberrant expression of downstream target genes in the disease. Our
previous study showed that ADAM19, a SMAD4 target gene, is downregulated through
epigenetic mechanisms in ovarian cancer with aberrant TGF-β/SMAD4 signaling. In this
study, we investigated the mechanism of downregulation of FBXO32, another SMAD4 target
gene, and the clinical significance of the loss of FBXO32 expression in ovarian cancer …